Daewoong Pharmaceutical
VC Fund
Seoul, South Korea
Daewoong Pharmaceutical is a VC fund in Seoul focused on Medical and Health Care. Daewoong Pharmaceutical Co., Ltd. has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare company by 2020.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Daewoong Pharmaceutical invests in
Stages Daewoong Pharmaceutical invests in
Countries Daewoong Pharmaceutical invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Investment Focus
Industry
- Medical 7 (39%)
- Health Care 7 (39%)
- Biotechnology 7 (39%)
- Pharmaceutical 6 (33%)
- Biopharma 2 (11%)
Stage
- Seed 6 (33%)
- Corporate Round 4 (22%)
- Series A 3 (17%)
- Series B 2 (11%)
- Series C 1 (6%)
Country
- South Korea 10 (56%)
- United States 4 (22%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jae-chun Yoon
Co-CEO
|
Co-CEO | Total investments: 0 | Find email | |
Woong-yeol Yang
Chief of Representative - Indonesia
|
Chief of Representative - Indonesia | Total investments: 0 | Find email | |
Lee Chang-jae
CEO and President
|
CEO and President | Total investments: 1 | Find email | |
Seng-Ho Jeon
Co-CEO
|
Co-CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
PROMEDIUS
|
Promedius is a MedTech startup, based in Seoul, Korea, focusing on optimizing radiologists workflow of medical imaging interpretation to drive improved patient outcomes. Our platform, AIdant, is providing an AI-enabled medical imaging cloud solution for individual doctors, medical institutions, and teleradiology centers. We believe ourcomprehensive zero-footprint AI solution can cover the geographic issues, after-hour issues, and lack of the radiologists issue in the diagnostic imaging market. | $14M / Series B / Jun 05, 2026 | |
TR
|
TR is a digital healthcare company that designs and develops medical devices and electronic products. | Corporate Round / May 15, 2026 | |
Vincere Biosciences
|
Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD). | $5M / Series A / Apr 01, 2025 | |
AEON Biopharma
|
AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is dedicated to developing novel and proprietary treatment paradigms in order to improve patient outcomes and drive increased value for patients, physicians, and payers. | $15M / Post-IPO Debt / Mar 19, 2024 | |
BeauBrain Healthcare
|
Alzheimer’s Disease is one of the most prevalent neurodegenerative diseases causing insufferable pain to patients and their families. There are over 55 million people worldwide living with dementia, and Alzheimer’s Disease is the most common form of dementia. Unfortunately, the aging population will only exacerbate the prevalence of the disease,yielding immense medical costs in addition to the already devastating social burden. At BeauBrain Healthcare, we are revolutionizing the current treatment paradigm from “post-diagnosis treatment” to “pre-emptive intervention.”Our solutions enable early identification of the disease through predictive analysis of disease-specific biomarkers (Amyloid Beta, Tau, Neurodegeneration), and a personalized cognitive training platform (DTx). Ultimately, our long-term vision is to realize precision medicine for Alzheimer’s disease through the biomarker data generated from our diverse solutions combined with a vast amount of genetic data. | $2.3M / Seed / Dec 22, 2023 | |
Liflex Science
|
Liflex Science provides RNA treatment for degenerative arthritis and is a professional in musculoskeletal illnesses. | Seed / Nov 30, 2023 | |
|
Biome ATS
|
BioM ATS intends to provide the fundamental infrastructure required to progress the complex strain design platform and foster technical collaboration with microbiome firms through proof-of-concept (POC) of the complex strain design technology. It is a strategy to begin the platform business in earnest by the end of the year, with an emphasis onplatform advancement and collaboration with industry, academia, research institutes, and the military. | $1.5M / Seed / Jun 28, 2023 | |
Biomatz
|
Biomatz is a biotechnology company specializing in microbiome therapeutics. Their proprietary platform designs cooperative microbial consortia by isolating and analyzing complex gut microbiota interactions, facilitating the development of live biotherapeutic products. It aims to advance personalized medicine and gut health solutions withapplications spanning pharmaceuticals, nutraceuticals, and functional foods. | $1.5M / Seed / Jun 28, 2023 | |
|
Vincere Biosciences
|
Vincere Biosciences is a JLABS incubator company whose mission is to develop drugs to halt the progression of Parkinson's disease (PD). | $2M / Corporate Round / Jun 12, 2023 | |
CellMEAT
|
CellMEAT is a food technology that supplies protein for the coexistence of the earth and mankind. The company provides meat for the food market. The company's contact mode is at its physical address. | $13.2M / Series A / May 24, 2023 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Daewoong Pharmaceutical invest in?
Daewoong Pharmaceutical invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Corporate Round stage. Most of the 18 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Daewoong Pharmaceutical?
Public channels for Daewoong Pharmaceutical include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Daewoong Pharmaceutical?
The team at Daewoong Pharmaceutical includes Jae-chun Yoon (Co-CEO), Woong-yeol Yang (Chief of Representative - Indonesia) and Lee Chang-jae (CEO and President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
